AAPL 192.4902 0.7591% MSFT 429.38 0.9498% GOOG 179.04 0.325% GOOGL 177.45 0.2996% AMZN 182.02 -0.8282% NVDA 947.4001 -0.0422% META 464.53 -0.9193% TSLA 186.0554 6.3478% TSM 153.42 -0.0847% LLY 803.85 2.6392% V 276.17 -0.8509% AVGO 1399.41 -1.0339% JPM 198.68 1.585% UNH 522.2967 0.9796% NVO 134.5401 1.2265% WMT 64.9 1.1218% LVMUY 166.815 -1.2052% XOM 118.03 -0.5393% LVMHF 846.034 0.1224% MA 457.885 -0.3862%

Penumbra Inc

Healthcare US PEN

200.25USD
-1.19(0.59%)

Last update at 2024-05-21T18:52:00Z

Day Range

198.47201.15
LowHigh

52 Week Range

180.93348.67
LowHigh

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax 3.89M -10.50200M -38.01800M 50.13M 1.61M
Minority interest 0.00000M 2.66M -3.55500M -0.27900M 0.17M
Net income -2.00200M 2.62M -19.25700M 48.46M 6.60M
Selling general administrative 449.72M 378.33M 287.07M 272.73M 226.38M
Selling and marketing expenses - - - - -
Gross profit 535.21M 475.38M 338.18M 371.96M 292.53M
Reconciled depreciation 24.32M 16.41M 12.89M 8.10M 6.17M
Ebit -18.23900M -23.90900M -51.83300M 39.40M 54.65M
Ebitda 6.08M -7.50100M -38.94200M 47.51M 60.82M
Depreciation and amortization 24.32M 16.41M 12.89M 8.10M 6.17M
Non operating income net other -2.32700M -3.93900M -0.34300M -0.22700M -3.60500M
Operating income -18.23900M -7.50100M -38.94200M 47.51M -0.85200M
Other operating expenses 841.05M 755.09M 599.35M 499.90M 414.95M
Interest expense 0.14M 16.07M 17.37M 12.19M 0.00000M
Tax provision 5.89M -13.12500M -18.76100M 3.13M -4.47800M
Interest income 0.14M 0.94M 1.27M 2.85M 2.96M
Net interest income 0.14M 0.94M 1.27M 2.85M 2.96M
Extraordinary items - - - - -0.07500M
Non recurring - - - - -30.83500M
Other items - - - - -
Income tax expense 5.89M -13.12500M -18.76100M 3.13M -4.40300M
Total revenue 847.13M 747.59M 560.41M 547.40M 444.94M
Total operating expenses 529.12M 482.88M 377.12M 324.46M 262.55M
Cost of revenue 311.93M 272.21M 222.24M 175.44M 152.41M
Total other income expense net 22.13M -3.00100M 0.92M 2.63M -31.33900M
Discontinued operations - - - - -
Net income from continuing ops -2.00200M 2.62M -19.25700M 47.00M 2.91M
Net income applicable to common shares -2.00200M 5.28M -15.70200M 48.46M 6.60M
Preferred stock and other adjustments - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 1370.89M 1244.25M 822.98M 665.90M 515.01M
Intangible assets 81.16M 90.62M 10.64M 25.41M 27.25M
Earning assets - - - - -
Other current assets 30.28M 29.16M 18.73M 14.85M 12.20M
Total liab 372.03M 290.32M 185.19M 180.29M 92.59M
Total stockholder equity 998.86M 953.93M 641.50M 485.89M 422.24M
Deferred long term liab 5.10M 5.80M - - 7.59M
Other current liab 97.14M 99.80M 3.00M 4.29M 57.89M
Common stock 0.04M 0.04M 0.04M 0.04M 0.03M
Capital stock 0.04M 0.04M 0.04M 0.04M 0.03M
Retained earnings 43.90M 45.91M 40.62M 57.52M 9.06M
Other liab 3.28M 3.56M 8.01M 15.25M 26.53M
Good will 166.05M 166.39M 8.37M 7.66M 7.81M
Other assets 77.01M 78.68M 138.10M 34.25M 33.81M
Cash 69.86M 59.38M 69.67M 72.78M 67.85M
Cash and equivalents 69.86M 59.38M 69.67M 72.78M 67.85M
Total current liabilities 144.93M 123.20M 105.93M 91.05M 66.06M
Current deferred revenue 9.16M - 82.80M 63.34M -
Net debt 165.91M 114.17M 7.61M 9.52M -67.85000M
Short term debt 11.95M 9.98M 6.03M 8.31M 0.00000M
Short long term debt - - - - -
Short long term debt total 235.77M 173.55M 77.28M 82.30M -
Other stockholder equity 963.04M 910.61M 598.30M 430.66M 415.08M
Property plant equipment 290.97M 227.09M 48.17M 131.92M 32.61M
Total current assets 755.70M 681.47M 617.70M 463.13M 410.73M
Long term investments - - - - 0.00000M
Net tangible assets 751.65M 696.92M 622.49M 449.30M 384.39M
Short term investments 118.17M 195.50M 195.16M 116.61M 133.04M
Net receivables 203.38M 133.94M 114.61M 105.90M 81.90M
Long term debt - - - - -
Inventory 334.01M 263.50M 219.53M 152.99M 115.74M
Accounts payable 26.68M 13.42M 14.11M 15.11M 8.18M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - -3.71000M -0.27900M 0.17M
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -8.12400M -2.63000M 2.54M -2.32400M -1.94200M
Additional paid in capital - - - - -
Common stock total equity 0.04M 0.04M 0.04M 0.04M 0.03M
Preferred stock total equity - - - - -
Retained earnings total equity 43.90M 45.91M 40.62M 57.52M 9.06M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 12.79M 12.98M 8.71M 2.95M 0.88M
Deferred long term asset charges - - - - -
Non current assets total 615.19M 562.78M 205.28M 202.77M 104.28M
Capital lease obligations 235.77M 173.55M 77.28M 82.30M -
Long term debt total 24.86M 26.52M 27.07M 26.75M 0.00000M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 74.09M -3.07400M -76.33300M 18.03M 29.63M
Change to liabilities 23.93M -1.56500M 22.95M -13.59500M 15.56M
Total cashflows from investing activities 54.79M -21.73500M -104.14900M -12.71100M -0.38500M
Net borrowings -1.75100M -1.45100M -3.41800M -2.57000M -0.40400M
Total cash from financing activities 11.62M 0.84M 134.92M -8.95900M -9.81500M
Change to operating activities 9.57M 7.75M 14.39M 3.56M 16.46M
Net income -2.00200M 2.62M -19.25700M 47.00M 2.91M
Change in cash 10.48M -10.29100M -3.10900M 4.93M 17.21M
Begin period cash flow 59.38M 69.67M 72.78M 67.85M 50.64M
End period cash flow 69.86M 59.38M 69.67M 72.78M 67.85M
Total cash from operating activities -55.66100M 9.50M -33.24200M 26.65M 28.81M
Issuance of capital stock 0.00000M 0.00000M 134.76M 0.00000M 0.00000M
Depreciation 24.32M 16.41M 12.89M 8.10M 6.17M
Other cashflows from investing activities 74.09M -0.40000M -3.06000M -8.63600M -20.41400M
Dividends paid - - - - -
Change to inventory -74.63100M -51.55400M -56.98100M -41.40700M -22.28800M
Change to account receivables -69.85700M -21.34400M -8.29500M -25.02900M -25.76200M
Sale purchase of stock 21.55M 18.37M 151.30M 13.90M 12.79M
Other cashflows from financing activities -0.39300M -11.41800M 3.58M -15.37300M -16.64200M
Change to netincome 43.55M 57.18M 24.31M -28.38600M 19.32M
Capital expenditures 19.30M 21.18M 24.76M 22.11M 9.60M
Change receivables -69.85700M -21.34400M -8.29500M 25.03M -25.76200M
Cash flows other operating -0.97400M -9.32400M -8.86500M 4.00M 33.07M
Exchange rate changes - - - - -1.39500M
Cash and cash equivalents changes 10.75M -11.39700M -2.47400M -48.32200M 17.21M
Change in working capital -121.79800M -70.41900M -51.19000M -56.84200M -30.26000M
Stock based compensation 37.38M 65.76M 25.54M 21.48M 18.42M
Other non cash items 4.98M 9.22M 17.59M 5.08M 38.05M
Free cash flow -74.95900M -11.67800M -57.99800M 4.54M 19.20M

Fundamentals

  • Previous Close 201.44
  • Market Cap9980.26M
  • Volume83675
  • P/E Ratio243.94
  • Dividend Yield-%
  • EBITDA86.53M
  • Revenue TTM995.06M
  • Revenue Per Share TTM26.01
  • Gross Profit TTM 535.21M
  • Diluted EPS TTM1.06

Peer Comparison

Sector: Healthcare Industry: Medical Devices

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
PEN
Penumbra Inc
-1.19 0.59% 200.25 243.94 88.50 10.03 8.63 9.56 107.83
ABT
Abbott Laboratories
-0.4689 0.45% 102.74 37.15 23.15 4.67 4.97 4.88 19.38
SYK
Stryker Corporation
-0.23 0.07% 329.50 44.07 24.94 5.51 6.12 6.05 25.73
MDT
Medtronic PLC
0.57 0.68% 85.08 26.60 15.87 3.35 2.08 3.90 14.12
BSX
Boston Scientific Corp
0.36 0.48% 75.72 68.17 24.57 5.85 4.26 6.46 26.80

Reports Covered

Stock Research & News

Profile

Penumbra, Inc., together with its subsidiairies, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the Penumbra RED, JET, ACE, 3D Revascularization Device, and Penumbra ENGINE brands, as well as components and accessories; neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400, POD400, PAC400, and Penumbra SMART Coil brand names; and neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, BMX96, DDC, SENDit, and PX SLIM brands. It also provides neurosurgical aspiration tools for the removal of tissue and fluids under the Artemis Neuro Evacuation Device brand; aspiration-based thrombectomy systems for vascular applications under the Indigo System, Lightning, and CAT RX brand; and detachable embolic coil systems for peripheral embolization under the Ruby Coil and Ruby LP brand names. In addition, the company offers microcatheter for the delivery of detachable coils and occlusion devices under the LANTERN brand; and POD (Penumbra Occlusion Device) brand, as well as immersive 3D computer-based technology platform under the Real Immersive System brand; and a complementary device for use with Ruby Coil and POD for vessel occlusion under the Packing Coil and Packing Coil LP brands. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.

Penumbra Inc

One Penumbra Place, Alameda, CA, United States, 94502

Key Executives

Name Title Year Born
Mr. Adam Elsesser Co-Founder, Chairman, Pres & CEO 1962
Dr. Arani Bose M.D. Co-Founder & Director 1962
Ms. Maggie S. Yuen Chief Financial Officer 1972
Mr. Lambert Shiu Chief Accounting Officer 1980
Ms. Johanna Roberts Exec. VP, Gen. Counsel & Sec. 1972
Ms. Lynn Rothman Exec. VP & Chief Bus. Officer 1961
Mr. Ben Sorci Exec. VP of Operations NA
Mr. Pankaj Tiwari Exec. VP & Chief Information Officer NA
Ms. Jee Hamlyn-Harris Investor Relations Officer NA
Ms. Shruthi Narayan Director of Marketing - Vascular NA

Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).